Ace the Certified Nephrology Nurse 2025 Exam – Dive into Dialysis Mastery!

Erythropoiesis-stimulating agents (ESAs) are key pharmacological agents used to manage anemia in patients with chronic kidney disease (CKD). In CKD, the kidneys have a diminished capacity to produce erythropoietin, a hormone that stimulates the production of red blood cells in the bone marrow. The lack of erythropoietin leads to anemia, characterized by reduced hemoglobin levels and fatigue.

ESAs, such as epoetin alfa and darbepoetin alfa, mimic the action of erythropoietin, stimulating red blood cell production and helping to correct anemia. Their use has been shown to improve hemoglobin levels, reduce the need for blood transfusions, and enhance the quality of life for these patients. By addressing the underlying issue of insufficient erythropoietin production, ESAs play a critical role in the management of anemia associated with CKD.

On the other hand, iron supplements are often used in conjunction with ESAs to ensure that there is adequate iron available for hemoglobin synthesis, but they do not directly stimulate red blood cell production. Anticoagulants are used to prevent clotting and do not address anemia. Potassium binders are relevant in managing hyperkalemia, a